Safeguarding Patients and Taxpayers Act

S 1589, the Safeguarding Patients and Taxpayers Act, requires the U.S. Department of Health and Human Services Secretary to submit annual reports to Congress detailing how funds from the drug price negotiation program are spent. These reports must cover contractor use, fraud prevention efforts, staffing costs, data security, and dispute resolution related to negotiating drug prices under the Social Security Act. The bill directly affects the Secretary, Congress, and contractors working on the drug price negotiation program by mandating transparency in funding use. Key provisions include requiring detailed spending breakdowns (like employee vs. contractor costs) and prohibiting fund reprogramming for new programs or eliminating existing ones without congressional approval. The bill focuses on oversight of implementation funding, not on changing drug pricing itself.